Human heart tissues were 3D-printed at Prof. Tal Dvir's Laboratory for Tissue Engineering and Regenerative Medicine at Tel Aviv University. These will be used to test the cardiotoxicity of experimental drugs as part of a collaboration between the university's tech-transfer company, Ramot, and German pharmaceutical giant Bayer.
"We are excited to start this new collaboration with Tel Aviv University, which will address a new area of early assessment of safety and tolerability of drug candidates," said Eckhard von Keutz, head of Translational Sciences at Bayer.
Follow Israel Hayom on Facebook and Twitter
"We already have a global network of partners and this new project will enable Bayer to expand its open innovation activities to Israel, which provides a dynamic ecosystem for innovation in biotech and medical research."
Video: Courtesy of Tel Aviv University
Last April, Dvir's lab successfully produced the first-ever 3D-printed heart using tissue extracted from a patient.
This type of innovative technology could potentially revolutionize drug screening.
Drug candidates go through several stages of screening: First, the new compound is tested on human tissue cultures in Petri dishes. Next, it is administered to lab animals, then, the drug is approved for human clinical trials.
Dvir's 3D-printed tissues could make the process faster, cheaper, and more efficient, the university said.
"In a Petri dish, all the cells line up in 2D, and it's only one type of cell," Dvir said. "In contrast, our engineered tissues are 3D-printed, and therefore better resemble real heart tissues. Our printed tissues contain cardiac muscle, blood vessels, and the extracellular matrix which connects the different cells biochemically, mechanically, and electrically. Moving away from Petri dishes to 3D printed tissues could significantly improve drug tests, saving precious time and money with the hope of producing safer and more effective medication."
Dvir hopes to eventually offer Bayer the ability to do pre-clinical trials on complete printed organs.
"Our end goal is to engineer whole human hearts, including all the different chambers, valves, arteries, and veins – the best analog of this complex organ – for an even better toxicological screening process," he explained.
According to a press release by Bayer, Ramot licensed the technology to a spin-off company, Matricelf, whose first focus is on engineering personalized spinal-cord implants to treat paralyzed patients.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
